Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study will be to determine whether rapid remote limb ischemic preconditioning (RIPC) combined with acetazolamide can further reduce the incidence of acute mountain sickness (AMS) during the 6-hour hypoxic chamber.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ji Xunming,MD,PhD
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• People who live in plain areas all year round and have not been to an altitude of 1500 meters or more in the past 30 days;

• Sign the informed consent form voluntarily.

Exclusion Criteria:

• Chronic physical or mental diseases, including hypertension, diabetes, coronary heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, migraine, anxiety, depression, insomnia, etc.;

• The female is pregnant or in the period of preparing for pregnancy or breast-feeding;

• Have a history of smoking;

• Have a history of thrombosis in the upper limbs;

• Severe damage to local soft tissues of upper limbs, fractures, etc.;

• Allergic to sulfa;

• Are taking one or more drugs;

• Past laboratory tests suggest hypokalemia, hyponatremia, or liver and kidney damage;

• Patients unsuitable for enrollment in the clinical trial according to investigators decision making.